Our Company
We discover and develop plant-derived cell signalling molecules to address challenging medical conditions in humans and companion animals
QBiotics has a 20 year track record in applying a scientifically-based, data-driven approach to the discovery of novel, plant-derived small molecule scaffolds for applications in human and animal health using our proprietary discovery platform EcoLogic™.
Our current focus is on two unique clinical assets in oncology and wound healing
We have two high-value, inter-related programmes in oncology and wound healing which we are co-developing for both the human and companion animal markets.
Our lead oncology product, tigilanol tiglate, is a novel small molecule that is administered intratumourally and has "agnostic" activity with the potential to treat a broad range of solid tumours, either as a monotherapy or in combination with checkpoint inhibitor drugs (see our oncology programme).Four human clinical trials are either in place, or in late stage planning, where our drug candidate, tigilanol tiglate, will be investigated for its potential across a range of cancer types, including Head and Neck Squamous Cell Carcinoma, Melanoma and Soft Tissue Sarcoma.
In companion animals, tigilanol tiglate has been registered and is marketed (branded as STELFONTA®*) as a veterinary pharmaceutical for treatment of canine mast cell tumours in the US, Europe and Australia. Clinical trials are in progress to determine efficacy of tigilanol tiglate in other solid tumors and species. (*This link will take you to a product site that contains information that may not comply with the Australian regulatory requirements.)
Our lead wound healing candidate, EBC-1013, is a novel, semi-synthetic small molecule formulated as a topical gel. Preclinical models and veterinary clinical data show its potential to treat a wide range of difficult to manage wounds including chronic non-healing and traumatic acute wounds, as well as burns. This programme is currently in early clinical stage for veterinary applications and in formal preclinical development for humans. Learn more about our wound healing programme.
We have proven ability to successfully partner and to commercialise our products
The potential of our products, and the quality of the underpinning science, is recognised in our commercial partnerships with leading global pharmaceutical companies.
STELFONTA*, the veterinary formulation of our oncology drug tigilanol tiglate, has been approved for treatment of canine mast cell tumours in the USA, Europe and Australia, and is being marketed and distributed under an agreement with Virbac, a global specialist animal health company. (*This link will take you to a product site that contains information that may not comply with the Australian regulatory requirements.)
We also have a clinical collaboration with MSD (tradename of Merck & Co. Inc, Kenilworth, NJ, USA) to evaluate the use of tigilanol tiglate as a human pharmaceutical in combination with the their immune checkpoint inhibitor drug Keytruda® (pembrolizumab) in patients with unresectable melanoma.
We have strong intellectual property protection for all our products
All our products are protected by patent families that encompass both composition of matter and use in all major jurisdictions. We also have an ongoing programme of new patent applications and patent extension activities.
A discovery pipeline underpins our potential for long-term growth
Our EcoLogic™ discovery technology provides future opportunities to expand our portfolio of therapeutic indications.
The first of these new areas, a discovery stage, next-generation antibiotic programme is ready to progress to development once our current clinical products are commercialised.
Our Story
2000
2000
2000
2003
2002-2004
2004
2004
2005
2005
2006
2006
2007
2007
2008
2008
>200 cases (89 MCT)
2009-2013
2010
2010
2010-2014
2013
2014
2015
2015
2015
2017
2018
2019
2019
2019
2019
2019
2019
2020
2020
2020
2020
2020
2021
2021
2021